Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

Slides:

Advertisements

Similar presentations

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Advertisements

Chronic Idiopathic Urticaria:

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Suppression of Basophil FcεRI Activation by Serum from Active Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Subjects Patricia M. Sterba, Robert.

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study Theodora Kanni, Maria Argyropoulou,

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial Hywel C. Williams,

Shyam Joshi, MD, David A. Khan, MD

Expanding Our Understanding of Human Skin Aging

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis Marta Ferrer, MD, PhD, Ana Giménez-Arnau,

Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Clinical Snippets Journal of Investigative Dermatology

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031 David C.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea Emilie Sbidian, Éric Vicaut, Henri Chidiack,

Devita Surjana, Gary M. Halliday, Andrew J. Martin, Fergal J

Databases for Clinical Research

Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari

Clinical Snippets Journal of Investigative Dermatology

Research Techniques Made Simple: Cost-Effectiveness Analysis

Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,

Alexander Egeberg, Gregor B. E. Jemec, Alexa B

Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola

Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria Keith C.P. Wu, Zarif K. Jabbar-Lopez Journal.

Tamar Nijsten Journal of Investigative Dermatology

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

Early decreases in blood eosinophil levels with reslizumab

More Than Many: How to Manage the Most Frequent Cancer?

Volume 61, Issue 4, Pages (April 2002)

Clinical Snippets Journal of Investigative Dermatology

Minutes of the Board of Directors Meeting

Journal of Investigative Dermatology

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Clinical Snippets Journal of Investigative Dermatology

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Research Techniques Made Simple: Itch Measurement in Clinical Trials

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Journal of Investigative Dermatology

John A. Eckman, MD, Patricia M

Society for Investigative Dermatology 2010 Meeting Minutes

Journal of Investigative Dermatology

Democratizing the Clinical Trials Agenda in Dermatology

What is an “eosinophilic phenotype” of asthma?

Erratum Journal of Investigative Dermatology

Research Snippets Journal of Investigative Dermatology

BJD Editor’s Choice Journal of Investigative Dermatology

Cells to Surgery Quiz: February 2019

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Hot on the Trail of Genes that Shape Our Fingerprints

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Volume 128, Issue 4, Pages (April 2005)

Journal of Investigative Dermatology

Engaging the Patient’s Perspective in Clinical Trials Research

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian.

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Lisa A. Beck, MD, Sarbjit Saini, MD

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Differences in Effects of Omalizumab on Late-Phase Responses to Allergen Challenge in the Skin and Nose at the Time of Basophil Hyporesponsiveness Miya.

Presentation transcript:

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin Trzaskoma, Henry N. Hulter, Karin Rosén, Patricia M. Sterba, Jean-Paul Courneya, Alan Lackey, Hubert Chen Journal of Investigative Dermatology Volume 137, Issue 4, Pages 958-961 (April 2017) DOI: 10.1016/j.jid.2016.11.025 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Effects of omalizumab on laboratory and clinical parameters. Change from baseline in (a) mean whole blood histamine concentration (ng/ml), in (b) mean blood basophil percentage (by flow cytometry), and in (c) mean weekly itch severity score in a subset of patients enrolled in ASTERIA I, ASTERIA II, and GLACIAL. *P < 0.05 versus placebo. Journal of Investigative Dermatology 2017 137, 958-961DOI: (10.1016/j.jid.2016.11.025) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Whole blood histamine concentrations correlate with blood basophils. Correlation between basophil percentage and blood histamine at (a) baseline and (b) week 12 for pooled phase 3 trial patients. Journal of Investigative Dermatology 2017 137, 958-961DOI: (10.1016/j.jid.2016.11.025) Copyright © 2016 The Authors Terms and Conditions